Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Items 101–200 of 538
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
“For other Firmicutes, Proteobacteria, and Verrucomicrobia, there is an agreement between at least three study results according to the increase in the abundance in several families, genus, and species pertaining to these phyla such as Lactobacillaceae (Firmicutes) [135,139,147,149], Christensenellaceae (Firmicutes) [1…”
BackgroundNagpal, R., Kurakawa, T., Tsuji, H., Takahashi, T., Kawashima, K., Nagata, S., Nomoto, K., & Yamashiro, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-10711-5 · Cited by 104
Self-citationAltered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease
Chiang, H.-L., & Lin, C.-H. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18067 · Cited by 104
The gut microbiome in Parkinson's disease: A culprit or a bystander?
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.01.004 · Cited by 103
Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
Pellegrino, A., Coppola, G., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · Nutrients · doi:10.3390/nu15081815 · Cited by 112
Wijeyekoon, R. S., Kronenberg-Versteeg, D., Scott, K. M., Hayat, S., Kuan, W.-L., Evans, J. R., Breen, D. P., Cummins, G., Jones, J. L., Clatworthy, M. R., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.01.018 · Cited by 104
Nuzum, N. D., Loughman, A., Szymlek-Gay, E. A., Hendy, A., Teo, W.-P., & Macpherson, H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.003 · Cited by 103
Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain
Xu, H.-M., Huang, H.-L., Zhou, Y.-L., Zhao, H.-L., Xu, J., Shou, D.-W., Liu, Y.-D., Zhou, Y.-J., & Nie, Y.-Q. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6699268 · Cited by 96
“Studies increasingly show that dysbacteriosis can lead to or exacerbate various neurological and psychiatric disorders, such as Parkinson’s disease [3, 4], Alzheimer’s disease [5– 7], autism spectrum disorder [8], multiple sclerosis [9], and epilepsy [10].”
BackgroundResultGut bacterial composition in a mouse model of Parkinson’s disease
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Naqib, A., Forsyth, C. B., Green, S. J., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2018) · Beneficial Microbes · doi:10.3920/bm2017.0202 · Cited by 102
“…by genetic and environmental factors, have been associated with a wide range of neurodegenenerative disorders, including PD (Bedarf et al. , 2017; Hasegawa et al. , 2015; Hill-Burns et al. , 2017; Hopfner et al. , 2017; Keshavarzian et al. , 2015; Li et al. , 2017; Petrov et al. , 2017;…”
Becker, A., Schmartz, G. P., Gröger, L., Grammes, N., Galata, V., Philippeit, H., Weiland, J., Ludwig, N., Meese, E., Tierling, S., et al. (2021) · doi:10.1101/2021.02.07.21251098 · Cited by 102
Becker, A., Schmartz, G. P., Gröger, L., Grammes, N., Galata, V., Philippeit, H., Weiland, J., Ludwig, N., Meese, E., Tierling, S., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2021.08.009 · Cited by 102
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Li, B., Evivie, S. E., Lu, J., Jiao, Y., Wang, C., Li, Z., Liu, F., & Huo, G. (2018) · Food & Function · doi:10.1039/c8fo01768a · Cited by 99
Huang, C., Li, Y., Feng, X., Li, D., Li, X., Ouyang, Q., Dai, W., Wu, G., Zhou, Q., Wang, P., et al. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00394 · Cited by 107
“Additionally, decreased Prevotellaceae and increased Lactobacilliaceae, which relate to neuroinflammation, were discovered in neurodegenerative diseases, such as PD (13).”
BackgroundOral Dysbiosis and Inflammation in Parkinson’s Disease
Fleury, V., Zekeridou, A., Lazarević, V., Gaïa, N., Giannopoulou, C., Genton, L., Cancela, J., Girard, M., Goldstein, R., Bally, J. F., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202459 · Cited by 107
Mihaila, D., Donegan, J., Barns, S., LaRocca, D., Du, Q., Zheng, D., Vidal, M., Neville, C., Uhlig, R., & Middleton, F. A. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218252 · Cited by 94
Suzuki, A., Ito, M., Hamaguchi, T., Mori, H., Takeda, Y., Baba, R., Watanabe, T., Kurokawa, K., Asakawa, S., Hirayama, M., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208313 · Cited by 88
Self-citationIs LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
Herrick, M. K., & Tansey, M. G. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00170-1 · Cited by 91
Of microbes and minds: A narrative review on the second brain aging
Calvani, R., Picca, A., Lo Monaco, M. R., Landi, F., Bernabei, R., & Marzetti, E. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00053 · Cited by 92
“In particular, a reduced abundance of Prevotellaceae, mucin producers that regulate intestinal permeability, was commonly reported in PD patients (31, 132, 135, 136), while Enterobacteriaceae were positively associated with the severity of postural instability and gait difficulty (31).”
BackgroundThe Gut and Parkinson’s Disease: Hype or Hope?
Scheperjans, F., Derkinderen, P., & Borghammer, P. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181477 · Cited by 86
“This would be in line with reports of a leaky gut and reduced levels of SCFAs and lipopolysaccharide binding protein in PD patients [62, 65, 66].”
ResultVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease
Chen, Q.-Q., Haikal, C., Li, W., & Li, J.-Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00218 · Cited by 89
Lombardi, V. C., Meirleir, K. L. D., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.004 · Cited by 101
Neuroimmune Interactions in the Gut and Their Significance for Intestinal Immunity
Brinkman, D. J., ten Hove, A. S., Vervoordeldonk, M. J., Luyer, M. D. P., & de Jonge, W. J. (2019) · Cells · doi:10.3390/cells8070670 · Cited by 95
The Endotoxin Hypothesis of Parkinson's Disease
Brown, G. C., Camacho, M., & Williams‐Gray, C. H. (2023) · Movement Disorders · doi:10.1002/mds.29432 · Cited by 90
Microbiome, Parkinson’s Disease and Molecular Mimicry
Miraglia, F., & Colla, E. (2019) · Cells · doi:10.3390/cells8030222 · Cited by 91
Microbiome changes: an indicator of Parkinson’s disease?
Haikal, C., Chen, Q.-Q., & Li, J.-Y. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0175-7 · Cited by 83
Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls
Hertzberg, V., Singh, H., Fournier, C. N., Moustafa, A., Polak, M. A., Kuelbs, C., Torralba, M., Tansey, M. G., Nelson, K. E., & Glass, J. D. (2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2021.1904994 · Cited by 88
“Gut microbiome dysbiosis has been associated with PD (37,39–45), multiple sclerosis (46–50), and autism spectrum disorder (51,52).”
BackgroundProbiotics: Protecting Our Health from the Gut
Varela-Trinidad, G. U., Domínguez-Díaz, C., Solórzano-Castanedo, K., Íñiguez-Gutiérrez, L., Hernández-Flores, T. D. J., & Fafutis‐Morris, M. (2022) · Microorganisms · doi:10.3390/microorganisms10071428 · Cited by 85
“Other associations between changes in GM and PD include the overgrowth of pathogens such as Helicobacter pylori [67] and constant changes in the microbiota depending on the stage of development of the disease [62].”
BackgroundTsao, S.-P., Nurrahma, B. A., Kumar, R., Wu, C.-H., Yeh, T.-H., Chiu, C.-C., Lee, Y.-P., Liao, Y.-C., Huang, C.-H., Yeh, Y.-T., et al. (2021) · Antioxidants · doi:10.3390/antiox10111823 · Cited by 79
“Gut microbiota dysbiosis is frequently reported in patients with PD, with increases in the relative abundance of Lactobacillus [57], Bifidobacterium [19], and Akkermansia [58] and decreases in the abundance of Prevotellaceae [22] and Lachnospiraceae [58] in fecal samples.”
BackgroundReview: The Role of Intestinal Dysbiosis in Parkinson’s Disease
Huang, Y., Liao, J., Liu, X., Zhong, Y., Cai, X., & Long, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.615075 · Cited by 75
“Various clinical studies have shown evidence indicating the occurrence of intestinal dysbiosis in PD patients compared with healthy controls, and the compositions of both fecal and mucosal microorganisms have been reported to change in PD patients (Hasegawa et al., 2015; Keshavarzian et al., 2015; Unger et al., 2016).”
BackgroundResultZhong, H., Xu, J., Yang, M., Hussain, M., Liu, X., Feng, F., & Guan, R. (2023) · Nutrients · doi:10.3390/nu15030496 · Cited by 87
“Another study showed dysregulation of gut microbiota homeostasis and reduced serum LPS binding protein levels in PD’s patients [122].”
BackgroundGut Microbiota in Neurological Disorders
Grochowska, M., Laskus, T., & Radkowski, M. (2019) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00561-6 · Cited by 84
Intestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 82
“Increased intestinal permeability leads to greater exposure to lumen antigens and bacteria [152], which in turn triggers the immune reactions and intestinal inflammation which initiating excessive α-synuclein expression in the colon or propelling its misfolding [153].”
BackgroundSingh, J., Vanlallawmzuali, Singh, A. K., Biswal, S., Zomuansangi, R., Lalbiaktluangi, C., Singh, B. P., Singh, P. K., Vellingiri, B., Iyer, M., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104068 · Cited by 76
Bile acid receptors and signaling crosstalk in the liver, gut and brain
Ferrell, J. M., & Chiang, J. Y. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.07.002 · Cited by 77
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease
Nishiwaki, H., Ueyama, J., Ito, M., Hamaguchi, T., Takimoto, K., Maeda, T., Kashihara, K., Tsuboi, Y., Mori, H., Kurokawa, K., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00724-z · Cited by 86
“4 and 5).”
Self-citationLorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
“Actinobacteria Bifidobacteriaceae Bifidobacterium 6 2 [95,97,98,100,102,107,111,119]”
Radulescu, C. I., Garcia-Miralles, M., Sidik, H., Bardile, C. F., Yusof, N. A. B. M., Lee, H. U., Ho, E. X. P., Chu, C. W., Layton, E., Low, D., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.011 · Cited by 69
“, 2015), and was associated with increased gut permeability (Hasegawa et al., 2015).”
Murakami, M., Iwamoto, J., Honda, A., Tsuji, T., Tamamushi, M., Ueda, H., Monma, T., Konishi, N., Yara, S., Hirayama, T. T., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy022 · Cited by 68
Potential Role of the Gut Microbiome in ALS: A Systematic Review
Wright, M. L., Fournier, C., Houser, M. C., Tansey, M., Glass, J., & Hertzberg, V. S. (2018) · Biological Research For Nursing · doi:10.1177/1099800418784202 · Cited by 65
Feng, Y., Song, Y., Zhou, J., Duan, Y., Kong, T., Ma, H., & Zhang, H. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2128037 · Cited by 80
“Moreover, LPS-binding protein harbors great potential significance as a biomarker of systemic inflammation in plasma samples from Parkinson’s disease patients (Hasegawa et al. 2015).”
BackgroundIntegrated Multi‐Cohort Analysis of the Parkinson's Disease Gut Metagenome
Boktor, J. C., Sharon, G., Verhagen Metman, L. A., Hall, D. A., Engen, P. A., Zreloff, Z., Hakim, D. J., Bostick, J. W., Ousey, J., Lange, D., et al. (2023) · Movement Disorders · doi:10.1002/mds.29300 · Cited by 68
“Dysbiosis, defined as a comparative alteration in microbiome composition,(18) has been implicated in PD and may be linked to the comorbidity of prodromal constipation.(19-30) Previous studies analyzing the fecal microbiome in PD via 16S amplicon profiling have found changes in multiple taxa compared to healthy control…”
BackgroundWhat Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review
Bonnechère, B., Amin, N., & van Duijn, C. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213665 · Cited by 78
Gut-to-Brain α-Synuclein Transmission in Parkinson’s Disease: Evidence for Prion-like Mechanisms
Chen, M., & Mor, D. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087205 · Cited by 76
Giuffrè, M., Moretti, R., Campisciano, G., da Silveira, A. B. M., Monda, V. M., Comar, M., Di Bella, S., Antonello, R. M., Luzzati, R., & Crocè, L. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113705 · Cited by 62
Yadav, S., Dwivedi, A., Tripathi, A., & Tripathi, A. K. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.07.007 · Cited by 67
Exploring the microbiota-gut-brain axis: impact on brain structure and function
Yassin, L. K., Nakhal, M. M., Alderei, A., Almehairbi, A., Mydeen, A. B., Akour, A. A., & Hamad, M. I. K. (2025) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2025.1504065 · Cited by 74
“This is in accordance with the findings of Hasegawa et al., 2015, where the abundance of Clostridium coccoides was found to be significantly lower in the stool samples of patients with PD than in those of healthy controls (Hasegawa et al., 2015).”
InfluentialGut microbiota, 1013 new pieces in the Parkinson's disease puzzle
Scheperjans, F. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000389 · Cited by 63
Can the gut be the missing piece in uncovering PD pathogenesis?
Chapelet, G., Leclair-Visonneau, L., Clairembault, T., Neunlist, M., & Derkinderen, P. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.11.014 · Cited by 59
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease
Marie, A., Darricau, M., Touyarot, K., Parr‐Brownlie, L. C., & Bosch‐Bouju, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212671 · Cited by 72
Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases
Girolamo, F., Coppola, C., & Ribatti, D. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.06.017 · Cited by 63
Benameur, T., Porro, C., Twfieg, M.-E., Benameur, N., Panaro, M. A., Filannino, F. M., & Hasan, A. (2023) · Brain Sciences · doi:10.3390/brainsci13081226 · Cited by 60
“investigated the intestinal microbiota in PD and healthy cohabitants, showing that PD patients exhibited a higher abundance of Lactobacillus compared to controls, whereas the Clostridium coccoides group and the Bacteroides fragilis group were lower in PD patients than in controls [120,121].”
ResultLiao, J.-F., Cheng, Y.-F., Li, S.-W., Lee, W., Hsu, C.-C., Wu, C.-C., Jeng, O.-J., Wang, S. Z., & Tsai, Y.-C. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.027 · Cited by 62
“…the results are still controversial, clinical studies in neuropsychiatric disorders and neurodegenerative condition increasingly reported the occurrence of gut dysbiosis (Hasegawa et al., 2015; Scheperjans et al., 2015; Vogt et al., 2017; Lubomski et al., 2019; Roy Sarkar and Banerjee, 2019).”
ResultGut microbiota in dementia with Lewy bodies
Nishiwaki, H., Ueyama, J., Kashihara, K., Ito, M., Hamaguchi, T., Maeda, T., Tsuboi, Y., Katsuno, M., Hirayama, M., & Ohno, K. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00428-2 · Cited by 70
Self-citationGut, oral and nasal microbiota and Parkinson’s disease
Shen, L. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01313-4 · Cited by 55
Foo, A. S. C., Soong, T. W., Yeo, T. T., & Lim, K. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00089 · Cited by 60
Kaur, G., Behl, T., BUNGAU, S. G., Kumar, A., Uddin, M. S., Mehta, V., Zengin, G., Mathew, B., Shah, M. A., & Arora, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606233050 · Cited by 64
“, Catabacter, Bifidobacterium 16S rRNA 89 66 [52]”
Joers, V., Masilamoni, G., Kempf, D., Weiss, A. R., Rotterman, T. M., Murray, B., Yalcin-Cakmakli, G., Voll, R. J., Goodman, M. M., Howell, L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105027 · Cited by 56
The Involvement of Neuroinflammation in the Onset and Progression of Parkinson’s Disease
Jurcău, A., Andronie-Cioară, F. L., Nistor-Cseppento, C. D., Pașcalău, N., Rus, M., Vasca, E., & Jurcău, M. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914582 · Cited by 64
“, 2015 [239] 52 PD patients and 36 controls -Lactobacillus (phylum Firmicutes) -Enterococcacecae (phylum Firmicutes) -Clostridium coccoides group (phylum Firmicutes) -Bacteroides fragilis (phylum Bacteroidetes)”
Nutritional habits, risk, and progression of Parkinson disease
Erro, R., Brigo, F., Tamburin, S., Zamboni, M. M., Antonini, A., & Tinazzi, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8639-0 · Cited by 58
“Many of these studies further point to a phenotype of intestinal low-grade inflammation [17] with disruption of intestinal tight junctions and reduction in levels of intestinal barrier-promoting proteins [15, 16].”
BackgroundReciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
Danilenko, V., Devyatkin, A., Marsova, M., Shibilova, M., Ilyasov, R. A., & Shmyrev, V. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s333887 · Cited by 57
Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson’s Disease
Perez-Pardo, P., Hartog, M., Garssen, J., & Kraneveld, A. D. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0129-2 · Cited by 51
Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
Kornum, D. S., Terkelsen, A. J., Bertoli, D., Klinge, M. W., Høyer, K. L., Kufaishi, H. H. A., Borghammer, P., Drewes, A. M., Brock, C., & Krogh, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071392 · Cited by 47
“To preserve a sufficient nutritional state, a feeding tube may be necessary for selected patients with weight loss.”
BackgroundBacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease
van Kessel, S. P., & El Aidy, S. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191780 · Cited by 52
“Akkermansia muciniphila, Bifidobacterium sp., Lactobacillus sp. 16S rRNA 212 136 Feces [17] none Lactobacillaceae, Barnesiellaceae, Enterococcaceae 16S rRNA 29 29 Feces [18] Corpobacillaceae, Lachnospiraceae (Blautia sp., Dorea sp., Roseburia sp., Coprococcus sp.) Bacteroides sp. 16S rRNA 38 34 Feces [19] Coprobacilla…”
BackgroundInfluentialTargeting Gut Microbiota Dysbiosis: Potential Intervention Strategies for Neurological Disorders
Wu, W., Kong, Q., Tian, P., Zhai, Q., Wang, G., Liu, X., Zhao, J., Zhang, H., Lee, Y. K., & Chen, W. (2020) · Engineering · doi:10.1016/j.eng.2019.07.026 · Cited by 57
Gastrointestinal disorders in Parkinson’s disease and other Lewy body diseases
Hirayama, M., Nishiwaki, H., Hamaguchi, T., & Ohno, K. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00511-2 · Cited by 66
“Our study 63 , along with a previous study 64 , showed that the degree of constipation in PD patients correlates with a decrease in the serum levels of LPS-binding protein (LBP).”
InfluentialSelf-citationVascellari, S., Melis, M., Palmas, V., Pisanu, S., Serra, A., Perra, D., Santoru, M. L., Oppo, V., Cusano, R., Uva, P., et al. (2021) · Biomolecules · doi:10.3390/biom11020144 · Cited by 48
Becker, A., Faßbender, K., Oertel, W. H., & Unger, M. M. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.09.032 · Cited by 49
Shiadeh, S. M. J., Chan, W. K., Rasmusson, S., Hassan, N., Joca, S. R. L., Westberg, L., Elfvin, A., Mallard, C. E., & Ardalan, M. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03504-2 · Cited by 59
“…biosynthesis presented elevated activity in both mucosal and fecal samples taken from patients with PD. Interestingly, the levels of serum lipopolysaccharide-binding protein (LBP) are lower in PD patients than in controls, particularly when the integrity of the intestinal mucosa is intact [201].”
Intestinal barrier function and metabolic/liver diseases
Ghosh, S. S., Wang, J., Yannie, P. J., & Ghosh, S. (2020) · Liver Research · doi:10.1016/j.livres.2020.03.002 · Cited by 56
A nutritional approach to microbiota in Parkinson’s disease
UYAR, G. Ö., & YILDIRAN, H. (2019) · Bioscience of Microbiota, Food and Health · doi:10.12938/bmfh.19-002 · Cited by 44
“Intestinal dysbiosis in PD has been reported in 12 articles from six countries: one from Finland, Japan and Russia, two from the USA, three from China, and four from Germany.”
BackgroundResultInfluentialSkowron, K., Budzyńska, A., Wiktorczyk-Kapischke, N., Chomacka, K., Grudlewska‐Buda, K., Wilk, M., Wałecka-Zacharska, E., Andrzejewska, M., & Gospodarek-Komkowska, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147820 · Cited by 56
“Type of Examination Study Population Preparation/Probiotic Bacteria Duration of theIntervention Results Statistical Significance References D EP R ES SI O N Pilot study 12 patients diagnosed with SSRI-treatment-resistant depression (mean age, 19.8 ± 5.7 years) Magnesium orotate (1600 mg), and probiotics (Lactobacillus…”
BackgroundInfluentialTsuji, H., Matsuda, K., & Nomoto, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01417 · Cited by 57
Self-citationBordoni, L., Gabbianelli, R., Fedeli, D., Fiorini, D., Bergheim, I., Jin, C. J., Marinelli, L., Stefano, A. D., & Nasuti, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223238 · Cited by 51
Rani, L., & Mondal, A. C. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.01.001 · Cited by 50
Abdolmaleky, H. M., & Zhou, J. (2023) · Nutrients · doi:10.3390/nu15153456 · Cited by 49
What Is the Evidence that Parkinson’s Disease Is a Prion Disorder, Which Originates in the Gut?
Kujawska, M., & Jodynis‐Liebert, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113573 · Cited by 51
“Recent studies on the gut microbiota have demonstrated gut dysbiosis [29–31,33–38] and/or small intestinal overgrowth (SIBO) [39–42] in PD patients, which correlated well with the severity of motor dysfunction [34,39,40] or with the GI impairment, such as constipation [33,34], bloating and flatulence [39], increased g…”
BackgroundInfluentialThe emerging science of precision medicine and pharmacogenomics for Parkinson's disease
Payami, H. (2017) · Movement Disorders · doi:10.1002/mds.27099 · Cited by 48
A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease
Mulak, A. (2018) · Movement Disorders · doi:10.1002/mds.27304 · Cited by 45
Gut microbiota as a potential player in mn-induced neurotoxicity
Tinkov, A. A., Martins, A. C., Avila, D. S., Gritsenko, V. A., Skalny, A. V., Santamaria, A., Lee, E., Bowman, A. B., & Aschner, M. (2021) · Biomolecules · doi:10.3390/biom11091292 · Cited by 45
Influence of human gut microbiome on the healthy and the neurodegenerative aging
Borrego-Ruiz, A., & Borrego, J. J. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112497 · Cited by 47
Ayaz, B. D., & Zubcevic, J. A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104677 · Cited by 45
Relationship between intestinal microbiota, diet and biological systems: an integrated view
Ferreira, R. D. S., Mendonça, L. A. B. M., Ribeiro, C. F. A., Calças, N. C., Guimarães, R. D. C. A., do Nascimento, V. A., Freitas, K. D. C., Carvalho, C. M. E., de Castro, A. P., & Franco, O. L. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1836605 · Cited by 49
“Intestinal dysbiosis seems to be associated with PD, for example, by the reduction of the bacterial families Prevotellaceae and Enterobacteriaceae, and increased proportion of Lactobacilliaceae (Hasegawa et al. 2015; Scheperjans et al. 2015; Unger et al. 2016).”
BackgroundHang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 47
Zapała, B., Stefura, T., Wójcik-Pędziwiatr, M., Kabut, R., Bałajewicz-Nowak, M., Milewicz, T., Dudek, A., Stój, A., & Rudzińska-Bar, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235698 · Cited by 44
Gut-brain axis and Alzheimer's disease: Therapeutic interventions and strategies
Singh, H., Chopra, C., Singh, H., Malgotra, V., Wani, A. K., Dhanjal, D. S., Sharma, I., Nepovimová, E., Alomar, S. Y., Singh, R., et al. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105915 · Cited by 43
Faecal Transplantation, Pro- and Prebiotics in Parkinson’s Disease; Hope or Hype?
Van Laar, T., Boertien, J. M., & Herranz, A. H. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191802 · Cited by 42
“114 Finally, many species of bacteria in the family 115 Enterobacteriaceae have been associated with PD, 116 putatively due to their production of hydrogen [11].”
BackgroundHasuike, Y., Endo, T., Koroyasu, M., Matsui, M., Mori, C., Yamadera, M., Fujimura, H., & Sakoda, S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109436 · Cited by 42
Is Porphyromonas gingivalis involved in Parkinson’s disease?
Olsen, I., Kell, D. B., & Pretorius, E. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03944-2 · Cited by 46
Environmental factors in Parkinson’s disease: New insights into the molecular mechanisms
Yuan, X., Tian, Y., Liu, C., & Zhang, Z. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.12.003 · Cited by 43
van Kessel, S. P., Bullock, A., van Dijk, G., & El Aidy, S. (2022) · mSystems · doi:10.1128/msystems.01191-21 · Cited by 41
Xu, R.-C., Miao, W.-T., Xu, J., Xu, W. V., Liu, M.-R., Ding, S., Jian, Y.-X., Lei, Y.-H., Yan, N., & Liu, H.-D. (2022) · Nutrients · doi:10.3390/nu14194163 · Cited by 49
“reported lowered LPS binding protein (LBP) in PD patients [66], indicating long-term enhanced permeability in PD patients’ intestinal barrier.”
BackgroundSingh, Y., Trautwein, C., Romani, J., Salker, M. S., Neckel, P. H., Fraccaroli, I., Abeditashi, M., Woerner, N., Admard, J., Dhariwal, A., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00628-1 · Cited by 43
The impact of indigenous microbes on Parkinson's disease
Sampson, T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.014 · Cited by 41
“appear positively correlated with disease severity (Barichella et al., 2018; Hasegawa et al., 2015; Lin et al., 2018).”
Monocyte mobilisation, microbiota & mental illness
van de Wouw, M., Boehme, M., Dinan, T. G., & Cryan, J. F. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.07.019 · Cited by 41
Vascellari, S., Melis, M., Cossu, G., Melis, M., Serra, A., Palmas, V., Perra, D., Oppo, V., Fiorini, M., Cusano, R., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.056 · Cited by 44
The role of innate immunity and inflammation in Parkinson´s disease
Öberg, M., Fabrik, I., Fabriková, D., Zehetner, N., & Härtlová, A. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13022 · Cited by 43
Bhoite, S. S., Han, Y., Ruotolo, B. T., & Chapman, M. R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102088 · Cited by 43
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.